These results are especially remarkable given that Cannata was participating in a Phase I safety trial that delivered the therapy at a relatively lowdose.
Scientific evidence now shows that some chemicals, especially endocrine disrupting compounds, can exert negative effects at extremely low levels of exposure, sometimes with more serious or different effects than at higher doses.